CHMP minded to turn down Alzheimer’s drug Aduhelm, says BiogenBiogen and Eisai have said that the EMA’s human medicines committee looks unlikely recommended approval of their Alzheimer’s Share XCHMP minded to turn down Alzheimer’s drug Aduhelm, says Biogenhttps://pharmaphorum.com/news/chmp-minded-to-turn-down-alzheimers-drug-aduhelm-says-biogen/
EMA starts review of Enhertu for HER2+ gastric cancerThe EMA has started its review of AstraZeneca and Daiichi Sankyo’s Enhertu for a second indication, as a Share XEMA starts review of Enhertu for HER2+ gastric cancerhttps://pharmaphorum.com/news/ema-starts-review-of-enhertu-for-her2-gastric-cancer/
EU starts review of Merck’s oral COVID drug molnupiravirThe EMA has started a rolling review of Merck & Co and Ridgeback Biotherapeutics’ much-anticipated oral antiviral molnupiravir Share XEU starts review of Merck’s oral COVID drug molnupiravirhttps://pharmaphorum.com/news/eu-starts-review-of-mercks-oral-covid-drug-molnupiravir/
EU backs broader use of Comirnaty as COVID booster than USThe EMA has given the go-ahead to the use of Pfizer and BioNTech’s COVID-19 vaccine Comirnaty as a Share XEU backs broader use of Comirnaty as COVID booster than UShttps://pharmaphorum.com/news/eu-backs-broader-use-of-comirnaty-as-covid-booster-than-us/
EMA looks at booster data for Pfizer/BioNTech COVID-19 jabThe EU regulator has started to review a marketing application filed by Pfizer and BioNTech for a third, Share XEMA looks at booster data for Pfizer/BioNTech COVID-19 jabhttps://pharmaphorum.com/news/ema-looks-at-booster-data-for-pfizer-biontech-covid-19-jab/
COVID-19: Celltrion’s therapeutic optionIn just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19. Share XCOVID-19: Celltrion’s therapeutic optionhttps://pharmaphorum.com/r-d/covid-19-providing-a-therapeutic-option/
EMA starts review of latecomer GSK/Sanofi COVID-19 vaccineThe EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started Share XEMA starts review of latecomer GSK/Sanofi COVID-19 vaccinehttps://pharmaphorum.com/news/ema-starts-review-of-latecomer-gsk-sanofi-covid-19-vaccine/
EMA finds possible link between mRNA COVID jabs and myocarditisThe EU medicines regulator has said that there is some evidence to suggest a possible link between mRNA-based Share XEMA finds possible link between mRNA COVID jabs and myocarditishttps://pharmaphorum.com/news/ema-backs-link-between-mrna-covid-jabs-and-myocarditis/
EU okays BMS’ azacitidine pill for first-line maintenance of AMLBristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that Share XEU okays BMS’ azacitidine pill for first-line maintenance of AMLhttps://pharmaphorum.com/news/eu-okays-bms-azacitidine-pill-for-first-line-maintenance-of-aml/
